Revolution Medicines, Inc. (RVMD)
RVMD moved a median of -0.07% 30 minutes after news, and +0.13% by the close. How RVMD actually reacts to news — the realized, point-in-time move the market made, measured across 574 labeled events over the last three years with zero look-ahead.
RVMD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 566 |
| 30-min | -0.07% | 47% | 566 |
| 60-min | -0.16% | 45% | 566 |
| to close | +0.13% | 54% | 563 |
| Middle 50% of RVMD reactions | -0.78% to +0.97% |
|---|---|
| Median reaction (30-min) | -0.07% |
| Measured reactions | 574 |
Half of all Revolution Medicines, Inc. news events land between -0.78% and +0.97% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RVMD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | -0.03% | 50% | +0.53% |
| Coverage initiations | 53 | -0.84% | 28% | -0.29% |
| Rating reiterations | 177 | -0.02% | 50% | -0.12% |
| Price-target raises | 51 | -0.10% | 49% | +0.27% |
| Price-target cuts | 11 | +0.28% | 64% | -0.15% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how RVMD ranks against every other measured name →
That’s how RVMD usually reacts — get an email when it moves on news →Email me when RVMD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RVMD's baseline. Nothing else.
Recent RVMD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer | Press release | GlobeNewswire | +0.49% | -1.13% | |
| Form 8-K Revolution Medicines, For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +1.00% | +3.58% | |
| Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer | Press release | GlobeNewswire | +0.85% | +0.00% | |
| Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer | Press release | GlobeNewswire | -1.02% | -1.02% | |
| New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer | Press release | GlobeNewswire | -0.48% | +0.41% | |
| Form 8-K Revolution Medicines, For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +2.56% | |
| Form 8-K Revolution Medicines, For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +1.29% | |
| U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer | Press release | GlobeNewswire | +0.69% | +1.62% | |
| Form 10-Q Revolution Medicines, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.19% | -0.13% | |
| Form 8-K Revolution Medicines, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | -0.13% | |
| Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress | Press release | GlobeNewswire | -0.19% | -0.13% | |
| Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 | Press release | GlobeNewswire | +0.68% | +4.60% | |
| Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer | Press release | GlobeNewswire | +0.65% | +3.36% | |
| European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process | Press release | GlobeNewswire | +0.19% | +0.43% | |
| Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 | Press release | GlobeNewswire | -1.29% | +0.46% | |
| Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 | Press release | GlobeNewswire | -0.31% | +4.23% | |
| Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer | Press release | GlobeNewswire | +1.96% | +3.80% | |
| Form 8-K Revolution Medicines, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +2.15% | |
| Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. | Press release | GlobeNewswire | +0.76% | +2.15% | |
| Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion | Press release | GlobeNewswire | +1.21% | +2.92% | |
| Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer | Press release | GlobeNewswire | -3.15% | +2.20% | |
| Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation | Press release | GlobeNewswire | -0.29% | -1.85% | |
| Form 10-Q Revolution Medicines, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.66% | -4.23% | |
| Form 8-K Revolution Medicines, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | -4.23% | |
| Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer | Press release | GlobeNewswire | -0.66% | -4.23% | |
| Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress | Press release | GlobeNewswire | -0.66% | -4.23% | |
| Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026 | Press release | GlobeNewswire | -1.61% | +0.26% | |
| Form ARS Revolution Medicines, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.96% | -0.12% | |
| Form DEFA14A Revolution Medicines, | SEC filing · Form DEFA14A | SEC EDGAR | +2.96% | -0.12% | |
| Form DEF 14A Revolution Medicines, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +2.96% | -0.12% | |
| Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | -0.29% | +1.55% | |
| Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -0.64% | -5.46% | |
| Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -0.64% | -5.46% | |
| Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -0.40% | -3.68% | |
| Form 8-K Revolution Medicines, For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | -3.68% | |
| Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | -0.40% | -3.68% | |
| Form 8-K Revolution Medicines, For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +1.02% | -0.57% | |
| Form 305B2 Revolution Medicines, | SEC filing · Form 305B2 | SEC EDGAR | -0.04% | -2.15% | |
| Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes | Press release | GlobeNewswire | -0.09% | +1.70% | |
| Form 8-K Revolution Medicines, For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | +3.41% | |
| Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes | Press release | GlobeNewswire | -0.73% | +7.70% | |
| Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer | Press release | GlobeNewswire | +1.01% | +2.75% | |
| Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting | Press release | GlobeNewswire | -0.88% | -1.03% | |
| Form 10-K Revolution Medicines, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.92% | +7.00% | |
| Form 8-K Revolution Medicines, For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +3.92% | +7.00% | |
| Form S-8 Revolution Medicines, | SEC filing · Form S-8 | SEC EDGAR | +3.92% | +7.00% | |
| Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress | Press release | GlobeNewswire | +3.92% | +7.00% | |
| Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +1.09% | -2.51% | |
| Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 | Press release | GlobeNewswire | -0.70% | +3.17% | |
| Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +1.20% | +0.66% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RVMD section they belong to.
Where else RVMD is measured.
RVMD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Revolution Medicines, Inc.'s median reaction calculated?
Every labeled RVMD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 574 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of RVMD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RVMD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.